search
Back to results

The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury (LBO_LCA)

Primary Purpose

Stroke, Brain Injuries, Traumatic

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Lifebloom One
Sponsored by
Lifebloom
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Stroke

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Stroke or traumatic brain injury more than 2 months old Unable to walk without assistance Expected length of stay equal to or greater than 4 months Exclusion Criteria: Anthropometric incompatibility with Oxilio Unable to walk prior to brain injury No functional upper limb Complete sensory deficit in the lower limb(s) Degenerative impairment (tumor, neurodegenerative disease, etc.)

Sites / Locations

  • Physical Medicine and Rehabilitation Department - Pitié-Salpêtrière Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Lifebloom One intervention

Arm Description

Outcomes

Primary Outcome Measures

Assessment of daily time spent standing change

Secondary Outcome Measures

10 meter walk test change
Functional Ambulation Categories (FAC) change
6-point scale. A score of 0 indicates that the patient is a non-functional ambulator, a score of 1, 2 or 3 denotes a dependent ambulator who requires assistance from another person in the form of continuous manual contact (1), continuous or intermittent manual contact (2), or verbal supervision/guarding (3) and a score of 4 or 5 describes an independent ambulator who can walk freely on: level surfaces only (4) or any surface (5=maximum score).
Berg Balance Scale change
In this 14-item scale, patients must maintain positions and complete moving tasks of varying difficulty. In most items, patients must maintain a given position for a specified time. Patients receive a score from 0-4 on their ability to meet these balance dimensions. A global score can be calculated out of 56. A score of 0 represents an inability to complete the item, and a score of 56 represents the ability to independently complete the item.
Fatigue Severity Scale change
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
6 minutes walk test
Barthel Index (BI)
The score of the BI is a summed aggregate and there is preferential weighting on mobility and continence. The scores are allotted in the following way: 0 or 5 points per item for bathing and grooming; 0, 5, or 10 points per item for feeding, dressing, bowel control, bladder control, toilet use, and stairs; 0, 5, 10, or 15 points per item for transfers and mobility. The Index yields a total score out of 100 - the higher the score, the greater the degree of functional independence.
Stroke Specific Quality of Life Scale
It is a self-report scale containing 49 items. Items are rated on a 5-point Likert scale. Higher scores indicate better functioning.
Patient Health Questionnaire - 9
The PHQ-9 contains the 9 items. Each item is evaluated on a severity scale ranging from 0 to 3 where the respondent is asked to rate how often each symptom occurred over the last 2 weeks (0-not at all; 1-several days; 2-more than half of the days or 3-nearly every day), yielding a total score ranging from 0-27. Score interpretation:1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; and 20-27 severe depression.
Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
Psychosocial Impact of Assistive Device Scale (F-PIADS)

Full Information

First Posted
July 13, 2023
Last Updated
July 26, 2023
Sponsor
Lifebloom
Collaborators
Pitié-Salpêtrière Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05977270
Brief Title
The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury
Acronym
LBO_LCA
Official Title
Evaluation of the Effects of Lifebloom One on Physical Activity After Acquired Brain Injury: A Single-Case Experimental Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lifebloom
Collaborators
Pitié-Salpêtrière Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to evaluate the effects of Lifebloom One in people who have suffered a stroke or a traumatic brain injury. The main questions to be answered are: Does Lifebloom One allow users to spend more time standing each day? Does Lifebloom One allow users to improve their balance and gait? Participants will use Lifebloom One during 8 weeks. For each participant, gait and balance are compared either with and without Oxilio or before and after Lifebloom One intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Brain Injuries, Traumatic

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single Case Experimental Design with multiple baselines across individuals
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lifebloom One intervention
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Lifebloom One
Intervention Description
LBO is made of Oxilio, an alternative to wheelchair placement for everyday use.
Primary Outcome Measure Information:
Title
Assessment of daily time spent standing change
Time Frame
Change from baseline to intervention phase
Secondary Outcome Measure Information:
Title
10 meter walk test change
Time Frame
Change from baseline to intervention phase
Title
Functional Ambulation Categories (FAC) change
Description
6-point scale. A score of 0 indicates that the patient is a non-functional ambulator, a score of 1, 2 or 3 denotes a dependent ambulator who requires assistance from another person in the form of continuous manual contact (1), continuous or intermittent manual contact (2), or verbal supervision/guarding (3) and a score of 4 or 5 describes an independent ambulator who can walk freely on: level surfaces only (4) or any surface (5=maximum score).
Time Frame
Change from baseline to intervention phase
Title
Berg Balance Scale change
Description
In this 14-item scale, patients must maintain positions and complete moving tasks of varying difficulty. In most items, patients must maintain a given position for a specified time. Patients receive a score from 0-4 on their ability to meet these balance dimensions. A global score can be calculated out of 56. A score of 0 represents an inability to complete the item, and a score of 56 represents the ability to independently complete the item.
Time Frame
Change from baseline to intervention phase
Title
Fatigue Severity Scale change
Description
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
Time Frame
Change from baseline to intervention phase
Title
6 minutes walk test
Time Frame
From the beginning and until the end of the intervention phase (during 8 weeks, one time per week)
Title
Barthel Index (BI)
Description
The score of the BI is a summed aggregate and there is preferential weighting on mobility and continence. The scores are allotted in the following way: 0 or 5 points per item for bathing and grooming; 0, 5, or 10 points per item for feeding, dressing, bowel control, bladder control, toilet use, and stairs; 0, 5, 10, or 15 points per item for transfers and mobility. The Index yields a total score out of 100 - the higher the score, the greater the degree of functional independence.
Time Frame
Before baseline, twice during the intervention phase, at immediate post-intervention
Title
Stroke Specific Quality of Life Scale
Description
It is a self-report scale containing 49 items. Items are rated on a 5-point Likert scale. Higher scores indicate better functioning.
Time Frame
Before baseline, at immediate post-intervention
Title
Patient Health Questionnaire - 9
Description
The PHQ-9 contains the 9 items. Each item is evaluated on a severity scale ranging from 0 to 3 where the respondent is asked to rate how often each symptom occurred over the last 2 weeks (0-not at all; 1-several days; 2-more than half of the days or 3-nearly every day), yielding a total score ranging from 0-27. Score interpretation:1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; and 20-27 severe depression.
Time Frame
Before baseline, at immediate post-intervention
Title
Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
Time Frame
at immediate post-intervention
Title
Psychosocial Impact of Assistive Device Scale (F-PIADS)
Time Frame
at immediate post-intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Stroke or traumatic brain injury more than 2 months old Unable to walk without assistance Expected length of stay equal to or greater than 4 months Exclusion Criteria: Anthropometric incompatibility with Oxilio Unable to walk prior to brain injury No functional upper limb Complete sensory deficit in the lower limb(s) Degenerative impairment (tumor, neurodegenerative disease, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Claire Kemlin, PhD
Phone
+33633307568
Email
claire.kemlin@lifebloom.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Marc Bardgett
Phone
+33609507060
Email
marc.bardgett@lifebloom.eu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eleonore Bayen, PUPH
Organizational Affiliation
Pitié-Salpêtrière Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Physical Medicine and Rehabilitation Department - Pitié-Salpêtrière Hospital
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eléonore Bayen, PUPH

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury

We'll reach out to this number within 24 hrs